News

After switching from idursulfase to Denali’s DNL310, patients demonstrated mean declines of more than 80% for both heparan sulfate and dermatan sulfate biomarkers at week 49 of treatment.

The associate professor of neuropsychology at the University of Miami Miller School of Medicine discussed how a new innovative tool can further characterize cognitive status and improve evaluation of agents in development for Alzheimer disease. [WATCH TIME: 2 minutes]

Milvexian at doses of 25 mg to 100 mg twice daily showed an approximate 30% relative risk reduction of ischemic stroke compared with placebo.

Even after adjusting for multiple confounding variables including recognized factors associated with cardiovascular diseases, PTSD plus insomnia remained an independent factor of major adverse cardiovascular events.

In comparison to nonresponders, those in the active treatment group who did respond well exhibited longer disease duration and lower baseline levodopa equivalent dose.

The director of medical outpatient services at the Kennedy Krieger Institute discussed the changes and implications of new CDC guidelines on developmental milestones for growing children.

The 0.2% topical gel, branded as Hyftor by Nobelpharma America, was approved in March 2022, and is indicated for individuals aged 6 years and older with TSC. It is the first topical therapy approved for this population.

The Rafa Laboratories 10-mg midazolam autoinjector is the first in market product of its kind, adding another option for the rescue of individuals with status epilepticus, a condition with crucial time implications in treatment.

Younger patients were more likely to have epilepsy-related imaging abnormalities, while older patients were more likely to have incidental abnormalities or those with an unknown relationship to epilepsy.

In a subanalysis of individuals with acute ischemic stroke with tandem lesions, treatment with the Penumbra system resulted in successful revascularization in almost 90% of patients.

Those who had used tobacco at any time demonstrated multiple significantly lower whole-brain measures than nonusers, including total cortical surface area, cortical volume, and total intracranial volume.

The chair of the nephrology division at Mayo Clinic provided context on recent findings linking inflammation and neurovascular damage in women with a history of severe preeclampsia, and how the community may react. [WATCH TIME: 2 minutes]

Results showed significantly smaller bilaterally gray matter volumes in Parkinson disease compared with controls, but no differences in brain-first or body-first subtypes on asymmetric atrophy.

Here's some of what is coming soon to NeurologyLive® this week.

Chaired by Augusto Miravalle, MD, of the University of Colorado, the presentations also feature Barry Hendin, MD, of the Center for Neurology and Spine; Ilana B. Katz Sand, MD, of Mount Sinai; Brett Fling, PhD, of Colorado State University; and Gavin Giovannoni, MBBCh, PhD, of Queen Mary University of London. [WATCH TIME: 1 hour, 59 minutes]

Plasma GFAP was increased in both presymptomatic and symptomatic mutation carriers compared with noncarriers, and in symptomatic compared with presymptomatic carriers.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease and movement disorders.

For patients with MCA M2 occlusions, use of the Zoom Stroke Solution resulted in significant decreases in National Institutes of Health Stroke Scale scores and no reported perforations or other reperfusion–catheter-related complications.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 26, 2022.

Between the 2 trials, patients showed significantly lower annualized relapse rates and mean number of gadolinium-enhancing lesions when treated with ublituximab relative to teriflunomide.

The transition period between summer and school represents a key time for children and adolescents to focus on sleep, correct poor sleep habits, and set themselves up for long-term success, both academically and physically.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Chris Winter, MD. [LISTEN TIME: 31 minutes]

Branaplam, an mRNA splicing modifier, was being evaluated in a cohort of 75 participants with early manifest Huntington disease, using change in mutant huntingtin protein as the primary outcome measure.

The associate professor of neuropsychology at the University of Miami Miller School of Medicine discussed the next steps in using the Cognitive Stress Test and the remaining questions from recent findings. [WATCH TIME: 4 minutes]

Investigators concluded there were no viable candidates for CVD risk phenotyping in sleep clinics because there were no strong links between any individual or type of oximetry pattern and incident cardiovascular disease.

The Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic discussed the complexities with identifying viable biomarkers for Parkinson disease, as well as interventions geared toward specific regions of the brain. [WATCH TIME: 4 minutes]

Treatment with remote ischemic conditioning performed twice daily for 2 weeks as an adjunct to guideline-based treatment resulted in higher odds of modified Rankin Scale scores between 0 and 1, and 0 and 2.

In a multiday ascending dose trial, pharmacokinetic analysis indicated a direct linear relationship between drug dosing concentration and blood plasma levels for each of the 5 days of dosing.